Q2 2019 EPS Estimates for RA Medical Systems Inc Decreased by Piper Jaffray Companies (RMED)
RA Medical Systems Inc (NYSE:RMED) – Equities researchers at Piper Jaffray Companies reduced their Q2 2019 EPS estimates for shares of RA Medical Systems in a research note issued on Monday, May 13th. Piper Jaffray Companies analyst M. O’brien now forecasts that the company will earn ($0.68) per share for the quarter, down from their prior forecast of ($0.49). Piper Jaffray Companies also issued estimates for RA Medical Systems’ Q3 2019 earnings at ($0.62) EPS, Q4 2019 earnings at ($0.58) EPS, FY2019 earnings at ($3.02) EPS, Q1 2020 earnings at ($0.54) EPS, Q2 2020 earnings at ($0.74) EPS, Q3 2020 earnings at ($0.71) EPS, Q4 2020 earnings at ($0.86) EPS, FY2020 earnings at ($2.85) EPS and FY2021 earnings at ($2.58) EPS.
RA Medical Systems (NYSE:RMED) last issued its quarterly earnings data on Monday, May 13th. The company reported ($1.16) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.78). The company had revenue of $1.75 million for the quarter, compared to analysts’ expectations of $1.22 million.
Shares of RMED opened at $4.18 on Thursday. The company has a market cap of $53.67 million and a P/E ratio of -1.25. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.28 and a current ratio of 11.64. RA Medical Systems has a twelve month low of $3.34 and a twelve month high of $22.00.
In other RA Medical Systems news, insider Dean Irwin sold 20,928 shares of the stock in a transaction that occurred on Thursday, April 11th. The stock was sold at an average price of $3.49, for a total transaction of $73,038.72. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.
Hedge funds have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in RA Medical Systems during the fourth quarter valued at approximately $98,000. Sit Investment Associates Inc. grew its holdings in RA Medical Systems by 161.4% during the fourth quarter. Sit Investment Associates Inc. now owns 27,450 shares of the company’s stock valued at $218,000 after purchasing an additional 16,950 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in shares of RA Medical Systems in the first quarter worth $238,000. Marshall Wace North America L.P. acquired a new stake in shares of RA Medical Systems in the third quarter worth $268,000. Finally, FNY Investment Advisers LLC acquired a new stake in shares of RA Medical Systems in the fourth quarter worth $287,000. Institutional investors own 31.93% of the company’s stock.
About RA Medical Systems
Ra Medical Systems, Inc, a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and disposable catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease.
Further Reading: Net Margin – Understanding the Different Kinds of Profit
Receive News & Ratings for RA Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RA Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.